콘텐츠로 건너뛰기
Merck
  • Extracellular Vesicles Secreted by Human Adipose-derived Stem Cells (hASCs) Improve Survival Rate of Rats with Acute Liver Failure by Releasing lncRNA H19.

Extracellular Vesicles Secreted by Human Adipose-derived Stem Cells (hASCs) Improve Survival Rate of Rats with Acute Liver Failure by Releasing lncRNA H19.

EBioMedicine (2018-08-06)
Yinpeng Jin, Junyi Wang, Hongchao Li, Shane Gao, Rongfeng Shi, Danjing Yang, Xianli Wang, Xi Wang, Liang Zhu, Xiaojin Wang, Chengwei Chen, Ke Ning, Zhengliang Gao, Jun Xu, Qingchun Fu
초록

It has previously been reported that human adipose-derived stem cells (hASCs) can promote the regeneration of damaged tissues in rats with liver failure through a 'paracrine effect'. Here we demonstrate a therapeutic effect of hASCs derived Extracellular Vesicles (EVs) on rat models with acute liver failure, as shown by the improvement of the survival rate by >70% compared to controls. Gene sequencing of rat liver revealed an increase in human long-chain non-coding RNA (lncRNA) H19 after hASC-derived EVs transplantation. When the H19 coding sequence was silenced in hASCs and EVs were then collected for treatment of rats with liver failure, we saw a decrease in the survival rate to 40%, compared to treatment with EVs generated from non-silenced hASCs. These data indicate that lncRNA H19 may be a potential therapeutic target for the treatment of liver failure.

MATERIALS
제품 번호
브랜드
제품 설명

Sigma-Aldrich
Quinalizarin, ≥95% (HPLC)